본문으로 건너뛰기
← 뒤로

Normothermic catheter-based intraperitoneal chemotherapy: Systematic review using the IDEAL framework.

메타분석 1/5 보강
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 📖 저널 OA 6% 2021: 0/5 OA 2022: 0/4 OA 2023: 0/7 OA 2024: 0/20 OA 2025: 7/146 OA 2026: 14/140 OA 2021~2026 2026 Vol.52(3) p. 111412
Retraction 확인
출처

Leveridge B, Ulucay E, Robb HD, Baggaley AE, Peters CJ, Hanna GB

📝 환자 설명용 한 줄

Peritoneal metastasis from (PM) remains a significant therapeutic challenge due to poor response to systemic chemotherapy, largely attributable to limited peritoneal drug penetration.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 연구 설계 systematic review

이 논문을 인용하기

↓ .bib ↓ .ris
APA Leveridge B, Ulucay E, et al. (2026). Normothermic catheter-based intraperitoneal chemotherapy: Systematic review using the IDEAL framework.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 52(3), 111412. https://doi.org/10.1016/j.ejso.2026.111412
MLA Leveridge B, et al.. "Normothermic catheter-based intraperitoneal chemotherapy: Systematic review using the IDEAL framework.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 52, no. 3, 2026, pp. 111412.
PMID 41564852 ↗

Abstract

Peritoneal metastasis from (PM) remains a significant therapeutic challenge due to poor response to systemic chemotherapy, largely attributable to limited peritoneal drug penetration. Normothermic catheter-based intraperitoneal chemotherapy (IPC) offers a promising alternative, enabling high local drug concentrations with reduced systemic toxicity. This review applies the IDEAL Framework to assess the evolution of normothermic catheter-based IPC for PM treatment. A systematic review identified 205 original studies and 47 trial protocols or registrations. Normothermic catheter-based IPC has advanced through IDEAL Stages 0 to 3, with preclinical data establishing feasibility, early-phase trials demonstrating safety and efficacy, and recent randomised controlled trials, mainly in Asia, suggesting survival benefit. However, uptake remains limited, and IDEAL Stage 4 data, including long-term follow-up and registry outcomes are lacking. These findings underscore normothermic catheter-based IPC's potential as part of multimodal PM treatment. Further prospective, globally representative trials and long-term data collection are needed to guide broader clinical adoption.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반